리툭시맙치료 후 완화에 도달한 난치성중증근무력증환자
Remission after Rituximab Therapy in Refractory Myasthenia Gravis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Myasthenia gravis (MG) is estimated to be refractory in approximately 10% of patients with generalized MG. A 35-year-old man was diagnosed as generalized MG with thymoma. Despite aggressive immunotherapies, his myasthenic symptoms relapsed five times within one year. We therefore administered rituximab for treating the refractory MG, and this resulted in remission. There are few reports on treating MG with rituximab, but this case suggests that rituximab can be an effective treatment option for refractory MG.
Abstract
Myasthenia gravis (MG) is estimated to be refractory in approximately 10% of patients with generalized MG. A 35-year-old man was diagnosed as generalized MG with thymoma. Despite aggressive immunotherapies, his myasthenic symptoms relapsed five times within one year. We therefore administered rituximab for treating the refractory MG, and this resulted in remission. There are few reports on treating MG with rituximab, but this case suggests that rituximab can be an effective treatment option for refractory MG.
참고문헌 (10)
- McGrogan A, "The incidence of myasthenia gravis: a systematic literature review", Neuroepidemiology, 34, pp.171~183 (2010)
- Drachman DB, "Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis", Ann N Y Acad Sci, 1132, pp.305~314 (2008)
- Iorio R, "Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis", J Neurol, 262, pp.1115~1119 (2015)
- Zisimopoulou P, "A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis", J Autoimmun, 52, pp.139~145 (2014)
- Sun F, "Interleulin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis", Muscle Nerve, 49, pp.487~494 (2014)
- Silvestri NJ, "Treatment-refractory myasthenia gravis", J Clin Neuromuscul Dis, 15, pp.167~178 (2014)
- Suh J, "Clinical characteristics of refractory myasthenia gravis patients", Yale J Biol Med, 86, pp.255~260 (2013)
- Catzola V, "Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis", J Neurol, 260, pp.2163~2165 (2013)
- Maddison P, "The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome", J Neurol Neurosurg Psychiatry, 82, pp.671~673 (2011)
- Anderson D, "Rituximab in refractory myasthenia gravis: a prospective, open-label study with long-term follow-up", Ann Clin Transl Neurol, 25, pp.552~555 (2016)